Expects Topline Results from First Multiple Ascending Dose Cohort by Year-end 2024 and to Initiate Rare Kidney Disease Cohorts in Early 2025 Cambridge, MA – September 30, 2024 – Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company advancing disease modifying therapies to transform the treatment of kidney disease, today announced that it has completed initial…
Study to further understand the established role that suPAR plays in causing kidney disease Cambridge, MA – May 13, 2024 – Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company advancing disease modifying therapies to transform the treatment of kidney disease, today announced that it has entered into a research collaboration with Primula Group to lever…
Proprietary Human anti-suPAR Monoclonal Antibody Demonstrated Safety and Reduction of Circulating Free suPAR, a Cause of Kidney Disease Plans to Initiate Phase 2 Basket Study in Glomerular Kidney Diseases in 2Q24 CAMBRIDGE, Mass., April 15, 2024— Walden Biosciences, Inc. (Walden), a private, venture-backed clinical development stage company focused on disease-modifying, transformative therapies for the treatment…
Expands partnership with laboratory of world-leading physician-scientist, Salim Hayek, M.D. Includes biomarker analysis from Walden’s Phase 1+ clinical study with Walden’s humanized anti-suPAR antibody, WAL0921 Anticipated to further demonstrate suPAR’s causative role in kidney diseases Cambridge, MA – January 10, 2024 – Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming…
Virtual event to include overview of Walden’s development programs and fireside chats highlighting the CKD landscape with Key Opinion Leaders Webcast to begin at 11:00 AM EST CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Walden Biosciences, Inc. (Walden), a private, venture-backed clinical-stage company focused on transforming the treatment of kidney diseases, today announced that…
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 Walden Biosciences, Inc. (Walden), a private, Series B, venture-backed clinical development stage company focused on transforming the treatment of kidney diseases, today announced that the first subject was dosed in the…
International Biopharma Executive Brings Nearly Twenty Years of Financial and Strategic Experience Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced the promotion of Curt Dewan, CFA to Chief Financial Officer. Mr. Dewan will serve as the Company’s first Chief Financial Officer and will…
Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Blaine McKee, Ph.D., Chief Executive Officer of Walden Biosciences, will present at the Oppenheimer 33rd Annual Healthcare Conference being held virtually from March 13-15, 2023. The presentation will take place at 8:40 a.m. EST on March…
Highlights multi-disciplinary, disease-modifying approach to developing novel therapies that directly target the kidney to prevent ongoing damage, slow disease progression and restore kidney function Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that members of its senior scientific leadership will participate in the 5th Annual…
CAMBRIDGE, Mass., Dec. 02, 2022 — Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Alex Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will give a presentation at the Antibody Engineering and Therapeutic Conference 2022, being held from December 4-8, 2022 in San…